Clinical Trials
26 trialsCarboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
DeLLphi-311
Amgen
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Chugai Pharmaceutical
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shanghai Henlius Biotech
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
STCube, Inc.
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
Guangzhou Institute of Respiratory Disease
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Hebei Medical University Fourth Hospital
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer
Lee's Pharmaceutical Limited
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer
Fujian Provincial Hospital
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy
Wake Forest University Health Sciences
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
China Medical University, China
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)